Duchenne muscular dystrophy (DMD) is a genetic condition that causes progressive muscle weakness, typically beginning in early childhood and primarily affecting boys. It occurs in roughly 1 in every 5,000 males and is the most common severe form of muscular dystrophy. DMD is caused by the absence of a critical protein called dystrophin, which muscles need to withstand the stress of everyday movement.
What Dystrophin Does and Why It Matters
Dystrophin is part of a protein complex that acts like an anchor inside muscle fibers. It connects the internal scaffolding of each muscle cell to the supportive network of proteins outside the cell. Every time a muscle contracts and relaxes, dystrophin absorbs and distributes the mechanical force so the cell membrane doesn’t tear.
Without dystrophin, muscle fibers sustain damage with ordinary use. The cells weaken, die, and are gradually replaced by fat and scar tissue. This process is irreversible and affects both skeletal muscles (the ones you use to walk, breathe, and lift things) and the heart muscle. The enlarged calves that many boys with DMD develop are actually a sign of this replacement: fat and fibrous tissue filling in where functional muscle used to be, a phenomenon called pseudohypertrophy.
How DMD Is Inherited
DMD follows an X-linked recessive inheritance pattern. The gene responsible for making dystrophin sits on the X chromosome. Because males have only one X chromosome (inherited from their mother) and one Y chromosome (from their father), a single mutation in the dystrophin gene is enough to cause the disease. Females, who carry two X chromosomes, almost always have a working backup copy, so they are typically carriers rather than affected individuals. A carrier mother has a 50% chance of passing the mutated gene to each son.
About one-third of DMD cases arise from new, spontaneous mutations with no family history at all. The mutations themselves are usually large deletions or duplications of sections within the gene, though smaller “spelling errors” in the genetic code also occur.
Early Signs in Toddlers and Preschoolers
The first clue is often delayed walking. Most children with DMD do learn to walk, but later than expected. By ages 2 to 4, parents typically notice clumsiness, frequent falls, and difficulty climbing stairs or keeping up with peers.
One hallmark sign is called the Gowers maneuver. When getting up from the floor, a child with DMD will “walk” his hands up his own legs to push himself upright because his hip and thigh muscles are too weak to stand normally. Enlarged, firm-feeling calf muscles alongside noticeable weakness elsewhere is another early red flag. These signs together are what usually prompt a visit to a neurologist or geneticist.
How DMD Is Diagnosed
The first screening step is a blood test measuring creatine kinase (CK), an enzyme that leaks out of damaged muscle cells. In boys with DMD, CK levels are dramatically elevated from birth, often 10 to 100 times the normal range. An extremely high CK level in a young boy with muscle weakness is a strong indicator, but it doesn’t confirm the diagnosis on its own.
Genetic testing provides definitive confirmation. Labs first look for large deletions or duplications in the dystrophin gene, which account for the majority of cases. If that test comes back normal, gene sequencing examines the full code letter by letter to catch smaller mutations. Identifying the exact mutation matters not just for diagnosis but also for determining which treatments a child may be eligible for.
How the Disease Progresses
DMD follows a fairly predictable course, though the timeline varies from person to person. During early childhood, muscle weakness is concentrated in the hips, thighs, and shoulders. Boys can still walk but may need leg braces or begin avoiding stairs. By the late elementary school years, walking becomes increasingly difficult.
Loss of independent walking historically occurred around age 12 to 13 on average. With modern care, including corticosteroid treatment, some boys retain the ability to walk into their mid-to-late teens. Data from patient registries show that those on sustained treatment have a median age at loss of walking closer to 16.5 years compared to 13 years in matched groups without the same level of intervention.
Once a wheelchair becomes necessary, weakness continues to spread to the arms, trunk, and respiratory muscles. Breathing support, first at night and eventually full-time, becomes necessary for most individuals during their late teens or twenties. The heart muscle also weakens progressively, requiring cardiac medications and monitoring.
Life Expectancy Today
Survival has improved substantially over the past few decades. For those born before 1970, the median life expectancy was about 18 years. For those born between 1970 and 1990, it rose to 24 years. For those born after 1990, receiving the benefit of modern respiratory support, cardiac care, and corticosteroids, median life expectancy has reached roughly 28 years, according to a large analysis published in the journal Neurology.
These numbers reflect population-level medians, meaning many individuals live longer. Advances in ventilatory support and heart failure management have been the biggest contributors to extended survival, and newer therapies may push these numbers further in the coming years.
Corticosteroids: The Standard Treatment
Corticosteroids remain the backbone of DMD management. They slow the rate of muscle deterioration, help maintain walking ability longer, and can delay the onset of breathing and heart problems. Treatment typically starts around age 4 to 6, though it can begin as early as age 2.
Three main options are available. Prednisone is the oldest and most studied. Deflazacort, a related drug approved for children 2 and older, works similarly and may cause slightly different side effect profiles. The newest option, vamorolone, is a synthetic steroid designed to preserve the muscle-protective benefits while reducing common steroid side effects like weight gain, bone thinning, and behavioral changes. Before starting any of these medications, children need to be up to date on live vaccines, since high-dose steroids suppress the immune system enough to make those vaccines unsafe.
Gene Therapy
The FDA has approved a gene therapy called Elevidys for individuals with DMD who are 4 years of age and older. It works by delivering a shortened, functional version of the dystrophin gene into muscle cells using an engineered virus as a delivery vehicle. The micro-dystrophin protein it produces is smaller than natural dystrophin (about one-third the size) but retains the key structural domains needed to protect muscle fibers.
Elevidys is given as a single intravenous infusion. It received traditional approval for patients who can still walk and accelerated approval for those who have already lost the ability to walk. One important limitation: it is not suitable for individuals with certain specific deletions in the dystrophin gene (in exon 8 or exon 9). Genetic testing results determine eligibility.
Daily Life and Ongoing Care
Managing DMD involves a coordinated team that typically includes a neurologist, cardiologist, pulmonologist, physical therapist, and orthopedic specialist. Regular cardiac monitoring with echocardiograms and pulmonary function testing with breathing tests become routine, usually every six to twelve months.
Physical therapy and stretching help maintain range of motion in joints that tighten as muscles weaken. Night splints for the ankles are common. As breathing muscles decline, sleep studies help determine when nighttime ventilation should begin. Many families also work with occupational therapists to adapt school environments and daily routines as mobility changes.
Bone health is a particular concern because both the disease itself and long-term steroid use weaken bones. Vitamin D and calcium supplementation are standard, and bone density scans help track fracture risk over time. Weight management also matters, since steroid-related weight gain puts extra strain on muscles that are already struggling.